Montelukast

Montelukast 10 mg is a prescription leukotriene receptor antagonist used for the long-term management of asthma and allergic rhinitis. It works by blocking leukotrienes, inflammatory chemicals in the body that contribute to airway swelling, bronchoconstriction, and allergy symptoms. These tablets are indicated for use in adults and adolescents 15 years of age and older.

Below is a quick overview of important facts for patients and caregivers:

Montelukast 10 mg tablets are used in individuals aged 15 years and older to:

• Manage symptoms of seasonal allergic rhinitis.
• Treat year-round allergies (perennial allergic rhinitis).
• Help prevent exercise-induced bronchoconstriction (airway tightening during exercise).
• Provide long-term prevention and control of asthma.

For allergic rhinitis, Montelukast should be reserved for patients who have an inadequate response or intolerance to alternative therapies due to the risk of serious neuropsychiatric events.

Montelukast tablets are leukotriene receptor antagonists that block inflammatory pathways involved in asthma and allergic rhinitis.

• It selectively binds to the cysteinyl leukotriene type-1 (CysLT1) receptor.
• It inhibits the action of leukotrienes (LTC4, LTD4, LTE4) released from mast cells and eosinophils.
• It reduces airway edema, smooth muscle contraction, and mucus production.
• It decreases nasal inflammation associated with allergic rhinitis.

By blocking leukotriene activity, Montelukast helps improve long-term control of asthma and allergy symptoms.

Always follow your healthcare provider’s instructions. General guidelines include:

• Take 10 mg orally once daily.
• For asthma, take it in the evening.
• For allergic rhinitis, it may be taken in the morning or evening.
• For exercise-induced bronchoconstriction, take at least two hours before exercise.
• May be taken with or without food.
• Do not take more than one dose within 24 hours.
• If a dose is missed, skip it and take the next dose at the regular time. Do not take two doses at once.
• Do not use Montelukast as a rescue medication for sudden asthma attacks. Keep a fast-acting inhaler available.

The recommended dosage depends on the condition being treated. Montelukast 10 mg tablets are approved for adults and adolescents 15 years of age and older.

Important dosage notes:

• Patients taking Montelukast daily for asthma or allergic rhinitis should not take an additional dose for EIB.
• Patients with both allergic rhinitis and asthma should take only one dose daily in the evening.

What If You Overdose on Montelukast?

Most reported overdoses were not associated with serious adverse events. In the event of an overdose:

• Employ general supportive measures
• Remove unabsorbed material from the gastrointestinal tract if clinically appropriate
• Monitor the patient clinically
• Provide supportive therapy as needed

It is unknown whether Montelukast is removed by peritoneal dialysis or hemodialysis. If an overdose is suspected, seek immediate emergency medical help or contact a poison control center.

The Montelukast tablets may cause side effects, some of which can be serious.

Common Side Effects

Commonly reported Montelukast side effects are listed below:

• Fever
• Upper respiratory infection
• Headache
• Cough
• Sore throat
• Diarrhea
• Abdominal pain
• Dizziness
• Flu-like symptoms
• Earache or ear infection
• Runny nose
• Sinus infection

Serious Side Effects

This medication may cause serious adverse reactions. Seek medical attention if you experience any of the following:

• Neuropsychiatric events, including mood changes, depression, agitation, anxiety, hallucinations, sleep disturbances, and suicidal thoughts or behavior
• Systemic eosinophilia, sometimes presenting with vasculitis consistent with Churg-Strauss syndrome

This is not a complete list of side effects. Contact your healthcare provider for medical advice about adverse reactions. You may report side effects to the FDA at 1-800-FDA-1088 or visit MedWatch.

While using this medication, the following warnings and precautions should be considered:

• Neuropsychiatric events: Mood changes, depression, agitation, sleep disturbances, hallucinations, and suicidal thoughts have been reported. Use with caution and discontinue if behavioral changes occur. Reserve for allergic rhinitis only when alternative therapies are ineffective or not tolerated.
• Corticosteroid substitution: Do not abruptly replace inhaled or oral corticosteroids with Montelukast tablets.
• Aspirin sensitivity: Patients with aspirin-sensitive asthma should continue avoiding aspirin and NSAIDs.
• Not for acute asthma: Do not use for sudden asthma attacks or status asthmaticus. Keep a short-acting rescue inhaler available.
• Eosinophilic conditions: Rare cases of systemic eosinophilia and vasculitis have been reported, particularly during corticosteroid reduction.

Pregnancy and Breastfeeding

Pregnancy: Available data from published studies have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, no adverse developmental effects were observed at doses significantly higher than the recommended human dose. It should be used during pregnancy only if clinically needed. Asthma should be adequately controlled during pregnancy.

Breastfeeding: Montelukast is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Montelukast and any potential adverse effects on the breastfed child.

Montelukast does not significantly inhibit cytochrome P450 enzymes. No dosage adjustment is required when it is co-administered with:

• Theophylline
• Prednisone or prednisolone
• Oral contraceptives
• Terfenadine
• Digoxin
• Warfarin
• Gemfibrozil
• Itraconazole
• Thyroid hormones
• Sedative hypnotics
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Benzodiazepines
• Decongestants
• Cytochrome P450 enzyme inducers

Strong cytochrome P450 enzyme inducers such as phenobarbital or rifampin may decrease montelukast plasma concentrations and potentially reduce its effectiveness. Clinical monitoring may be appropriate when these medications are used together. Patients should inform their healthcare provider about all over-the-counter drugs, supplements, and prescription medications they use before starting Montelukast tablets.

Montelukast is one of several controller medications used to manage asthma and allergic rhinitis. Other treatment options may be considered based on disease severity and individual response.

These medications contain different active ingredients and mechanisms of action and should not be substituted without medical guidance. Brand availability may vary by location and supply. Treatment selection should be determined by a healthcare provider based on asthma severity, allergy symptoms, patient-specific risk factors, safety profile, and clinical response.

Prescription asthma and allergy medications may be costly at many U.S. retail pharmacies. Ordering Montelukast online from Polar Bear Meds may help reduce overall costs while maintaining safety, quality, and reliability.

• Competitive pricing compared to many U.S. retail pharmacies.
• Medications sourced from licensed and reputable Canadian pharmacies.
• Properly dispensed prescription products under regulatory standards.
• Transparent pricing with no hidden fees.
• U.S. customers can order with a valid prescription.
• Simple online ordering with easy prescription upload.
• Discreet packaging with order tracking for added security.
• Shipping across the United States typically takes 3-5 business days via Xpress Post.
• Shipping timelines may vary depending on processing requirements and location.
• Dedicated customer support team to assist with prescriptions, orders, and delivery questions.
• Additional savings with coupon code WELCOMEPB10: 10% off your first order.

All Montelukast orders require a valid prescription. Medications are dispensed by licensed pharmacies that comply with applicable pharmacy regulations and safety standards.

• https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecaa9b4b-5941-4af5-930c-35e9f3b2b4ba
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10715380/
• https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug